3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Terminated
2
Unknown
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
23
Leukemia
3
Recurrence
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Higher-risk Myelodysplastic Syndrome
1
Hematologic Diseases
1
Dendritic Cell Sarcoma, Interdigitating
1
Bone Marrow Diseases
1
Interventions
venetoclax
2
fludarabine
2
fludarabine phosphate
1
blinatumomab
1
asciminib
1
Whole-Body Irradiation
1
Idarubicin
1
IPI-549
1
Filgrastim
1
Cytarabine
1
Cyclophosphamide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Leukemia, Myeloid
×
Azacitidine
×
Clear all
NCT07439211
2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1
Not yet recruiting
48 enrolled